tradingkey.logo

Helius Medical Technologies Inc

HSDT
5.500USD
+0.170+3.19%
Close 11/07, 16:00ETQuotes delayed by 15 min
74.86KMarket Cap
LossP/E TTM

Helius Medical Technologies Inc

5.500
+0.170+3.19%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Helius Medical Technologies Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Helius Medical Technologies Inc's Score

Industry at a Glance

Industry Ranking
136 / 209
Overall Ranking
335 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Helius Medical Technologies Inc Highlights

StrengthsRisks
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
Growing
The company is in a growing phase, with the latest annual income totaling USD 520.00K.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.90M shares, increasing 50.00% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.99.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 5.89, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 43.00K, representing a year-over-year decrease of 76.37%, while its net profit experienced a year-over-year decrease of 509.99%.

Score

Industry at a Glance

Previous score
5.89
Change
0

Financials

9.54

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.71

Operational Efficiency

2.57

Growth Potential

3.52

Shareholder Returns

7.11

Helius Medical Technologies Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 8.01, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.00, which is -3116920.00% below the recent high of 15.58 and -78080.00% above the recent low of -0.39.

Score

Industry at a Glance

Previous score
8.01
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 136/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

69
Total
7
Median
8
Average
Company name
Ratings
Analysts
Helius Medical Technologies Inc
HSDT
1
Blackstone Inc
BX
25
KKR & Co Inc
KKR
22
BlackRock Inc
BLK
20
Carlyle Group Inc
CG
19
Ares Management Corp
ARES
18
1
2
3
...
14

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 4.95, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 13.37 and the support level at 1.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.94
Change
0.01

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.238
Sell
RSI(14)
35.824
Neutral
STOCH(KDJ)(9,3,3)
29.841
Buy
ATR(14)
0.638
High Vlolatility
CCI(14)
-67.961
Neutral
Williams %R
63.333
Sell
TRIX(12,20)
-3.636
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
5.138
Buy
MA10
5.800
Sell
MA20
7.778
Sell
MA50
11.365
Sell
MA100
8.873
Sell
MA200
7.214
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 10.09%, representing a quarter-over-quarter increase of 452.12%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Fusion Summer Ltd
6.83M
--
Pantera Capital Partners LP
3.89M
--
Wayne (Morehead Daniel)
10.00K
--
Wealthspire Advisors LLC
6.00K
--
Desjardins Securities Inc.
4.00K
--
Leonite Fund I LP
3.26K
--
UBS Financial Services, Inc.
737.00
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 1.04, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.04
Change
0
Beta vs S&P 500 index
1.02
VaR
+10.53%
240-Day Maximum Drawdown
+98.63%
240-Day Volatility
+491.99%

Return

Best Daily Return
60 days
+141.67%
120 days
+4212.80%
5 years
+4212.80%
Worst Daily Return
60 days
-36.49%
120 days
-65.14%
5 years
-65.14%
Sharpe Ratio
60 days
+0.98
120 days
+1.38
5 years
+0.39

Risk Assessment

Maximum Drawdown
240 days
+98.63%
3 years
+99.93%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.15
3 years
-0.32
5 years
-0.20
Skewness
240 days
+15.45
3 years
+26.68
5 years
+34.32

Volatility

Realised Volatility
240 days
+491.99%
5 years
+259.67%
Standardised True Range
240 days
+22.93%
5 years
+2535.23%
Downside Risk-Adjusted Return
120 days
+4591.32%
240 days
+4591.32%
Maximum Daily Upside Volatility
60 days
+462.40%
Maximum Daily Downside Volatility
60 days
+296.24%

Liquidity

Average Turnover Rate
60 days
+1999.54%
120 days
+1017.16%
5 years
--
Turnover Deviation
20 days
-99.04%
60 days
+150.82%
120 days
+27.59%

Peer Comparison

Healthcare Equipment & Supplies
Helius Medical Technologies Inc
Helius Medical Technologies Inc
HSDT
5.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI